Compare IDN & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | SEER |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6M | 98.2M |
| IPO Year | 1999 | 2020 |
| Metric | IDN | SEER |
|---|---|---|
| Price | $5.22 | $1.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | 117.5K | ★ 128.6K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $21,968,000.00 | $16,376,999.00 |
| Revenue This Year | $12.21 | $22.37 |
| Revenue Next Year | $12.44 | $30.00 |
| P/E Ratio | $568.70 | ★ N/A |
| Revenue Growth | ★ 14.20 | 12.11 |
| 52 Week Low | $2.17 | $1.62 |
| 52 Week High | $7.48 | $2.41 |
| Indicator | IDN | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 26.00 | 38.62 |
| Support Level | $5.97 | $1.84 |
| Resistance Level | $6.14 | $1.92 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 14.49 | 13.89 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.